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The presence of telomerase activity in a glioma may be a predictor of its malignant potential. Activation of telomerase is regulated at
the transcriptional level of the human telomerase reverse transcriptase (hTERT). Here, we evaluated whether the amount of hTERT
mRNA provides a molecular marker of glioma malignancy that would have clinical utility. We used a real-time RT–PCR to assess the
number of hTERT transcripts in primary tumour samples derived from 70 glioma patients. Results were standardised by quantifying
the number of ABL transcripts as internal control and expressed as hTERT/ABL ratio. The percentage of patients with detectable
hTERT mRNA markedly increased with enhanced malignancy: low-grade gliomas expressed hTERT in one out of 14 cases (7.1%),
anaplastic gliomas in four out of 13 cases (30.8%) and glioblastoma multiforme (GBM) tumours in 30 out of 43 cases (69.8%). The
mean hTERT/ABL ratio was significantly higher in GBMs than in non-GBMs. Subdividing hTERT/ABL ratios as low (p25%) and high
(425%), we found that the overall survival among hTERT-positive GBMs was significantly worse in high hTERT expressors than in low
hTERT expressors (P¼0.0082). We conclude that the amount of hTERT mRNA may represent a diagnostic and prognostic indicator
for GBM patients.
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Gliomas are the most common of primary brain tumours in
humans and form a complex group because of the great variability
in degree of malignancy that exists among them. The grade of
malignancy is one of the major factors in the prognosis of glioma
patients (DeAngelis, 2001). Patients with low-grade tumours
typically survive more than 5 years, patients with anaplastic
tumours about 3 years, and patients with glioblastoma multiforme
(GBM), glioma of the highest grade of malignancy, have the
poorest prognosis with median survival of less than 1 year despite
modern therapy. Molecular genetic research has led to an
increased knowledge of markers that are associated with glioma
malignancy and may be useful diagnostic and therapeutic targets.
In particular, malignant progression in gliomas has been
correlated with the presence of telomerase activity in tumour cells
(Langford et al, 1995).
Telomerase is a specialised reverse transcriptase enzyme that
maintains telomeres by adding telomeric TTAGGG repeats to the
ends of human chromosomes (Morin, 1989). Telomerase is
repressed in most normal human somatic cells, and without new
synthesis of telomeres the chromosomes shorten with progressive
cell division, eventually triggering either replicative senescence or
apoptosis when telomere length becomes critically short (Harley
et al, 1990). In contrast, cells that express a sufficient level of
telomerase activity escape from replication limitations and are
considered as immortal. Reactivation of telomerase is believed to
be an essential step during malignant tumour progression
(Counter et al, 1994). A strong association between the presence
of telomerase and malignancy has been established in nearly all
cancer types (reviewed in Shay et al, 2001). Importantly, high
telomerase activity is generally associated with high tumour
aggressiveness.
Studies of gliomas have shown that more than 50% of tumours
have telomerase activity, detection rates increasing with the grade
of malignancy (Langford et al, 1995; Nakatani et al, 1997; Le et al,
1998; Sugita et al, 2000). These observations have suggested that
the presence of such activity may indicate the malignant potential
of a glioma. However, the prognostic value of telomerase in
gliomas remains uncertain. Although telomerase activity has been
correlated with inferior survival in low-grade and anaplastic
astrocytomas, no clear relation has been determined between the
detection or relative level of telomerase activity and patient
survival in GBMs, the most common and most malignant gliomas
(Nakatani et al, 1997; Hiraga et al, 1998; Huang et al, 1999;
Kleinschmidt-Demasters et al, 2000).
The activation of telomerase is tightly regulated at the
transcriptional level of the human telomerase reverse transcriptase
(hTERT). Many studies have suggested that the transcription of
hTERT represents the rate-limiting step in telomerase expression,
and the detection of hTERT transcripts using RT–PCR revealed a
strong correlation with telomerase activity in the majority of Revised 25 September 2002; accepted 19 November 2002
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ytumours (reviewed in Pool et al, 2001). A recent method of real-
time PCR has greatly facilitated sensitive and quantitative
detection of hTERT mRNA. In this study, we evaluated the level
of hTERT transcripts in 70 primary gliomas and correlated them
with malignancy grade. In GBMs, we also studied the relation
between the amount of hTERT mRNA and patient survival. We
found that hTERT expression increased with malignancy grade and
was highly associated with GBMs. Within this important glioma
subgroup, the level of hTERT mRNA was predictive of patient
survival.
MATERIALS AND METHODS
Patients and samples
Primary tumour samples were obtained from 70 glioma patients at
surgical resection of their lesion. The samples for hTERT
expression analysis were taken from the material of resection
during the course of standard diagnostic procedure. According to
the French law on biomedical research, this is an epidemiological
study that does not have to be submitted to an Institutional Review
Board. Immediately after surgery, the samples were snap-frozen
and stored in liquid nitrogen until RNA extraction.
Histological diagnosis and grading of tumours were consistent
with the WHO criteria (World Health Organization, 2000). A total
of 14 tumours were classified as low-grade gliomas, 13 tumours
were anaplastic gliomas, and the remaining 43 tumours were
classified as GBMs. The details of tumour type and grade are given
in Table 1.
Among 70 glioma patients, 46 patients were male and 24 were
female. The mean age at diagnosis was 31.5712.2 years for
patients with low-grade tumours, 43.7712.7 years for patients with
anaplastic gliomas and 59.5710.7 years for patients with GBMs.
The median follow-up was 61 months (range, 32–184 months). In
two GBM cases, very early postsurgery death occurred. In most
cases, postsurgical treatments included radiotherapy and/or
various chemotherapy regimens. Note that in our GBM series,
postsurgical treatments had no prognostic impact (data not
shown).
Extraction of RNA and preparation of cDNA
Total RNAs were extracted from tumour samples using Trizol
s
reagent (GIBCO/BRL, Grand Island, NY, USA), according to the
manufacturer’s instructions. Sample RNA (1mg) was reverse
transcribed as reported elsewhere (Rolhion et al, 1999). In parallel,
reverse transcription reaction was set up without enzyme and then
the sample was processed to PCR as a control for DNA
contamination.
Quantitative real-time RT–PCR for hTERT mRNA
We assessed the number of hTERT mRNA transcripts using real-
time PCR in the LightCycler system (Roche Diagnostics, Meylan,
France). The amplification of hTERT mRNA was performed with
the DNA Master SYBRGreen I reagent set (Roche Diagnostics,
Meylan, France) using the following primers: forward primer 50-
GGAGCAAGTTGCAAAGCATTG-30 and reverse primer 50-
TCCCACGACGTAGTCCATGTT-30. Quantification of ABL tran-
scripts as an internal control for the amount and quality of cDNA
was performed for all samples, using the forward primer 50-
GCCGCTCGTTGGAACTCCAAGG-30 and reverse primer 50-
TGACTGGCGTGATGTAGTTTGCTT-30 (Tchirkov et al, 1998).
Several studies have confirmed that the ABL gene is an appropriate
reference in quantitative real-time PCR studies of both patholo-
gical and normal cells (Buonamici et al, 2002; Moniotte et al,
2001). During initial optimisation of PCR conditions, amplified
products were analysed using agarose gels to ensure correct
product size. Once the PCR product size was verified, the melting
temperature of the product determined with LightCycler melting-
curve analysis was used to control for the specificity of
amplifications. The number of transcripts in samples was
calculated with the LightCycler software, using the calibration
data obtained with serial dilutions of purified PCR products
containing known numbers of cDNA molecules of each gene
(Figure 1). The results of real-time PCR were given as the ratio
between hTERT and ABL transcripts, expressed as a percentage.
Glioma samples were analysed in a blind-trial fashion. All
experiments were performed in triplicate, with good consistency
of results (the mean coefficient of variation was 8.4%).
Statistical analysis
The overall survival time was calculated in months after initial
surgery date. For patients with hTERT-expressing GBMs, a receiver
operating characteristic (ROC) analysis was used to determine
which hTERT level best discriminated between those patients who
did not reach the median survival time (15 months for hTERT-
positive GBM patients) and the others (Bamber, 1975; Hanley and
McNeil, 1982). This method was valid since all patients had died by
the time of analysis. Kaplan–Meier estimation was used to
evaluate the overall survival and the log-rank statistics was used
to compare survival between subgroups of patients (Kaplan and
Meier, 1958). Other analyses of statistical links between biological
and clinical parameters were performed using standard tests.
RESULTS
hTERT mRNA expression in gliomas
We studied 70 gliomas for the presence of hTERT mRNA using a
real-time RT–PCR. Table 1 shows that low-grade gliomas
expressed hTERT in one out of 14 cases (7.1%), anaplastic gliomas
in four out of 13 cases (30.8%) and GBMs in 30 out of 43 cases
(69.8%). Thus, the frequency of hTERT expression significantly
increased with advanced glioma malignancy (w
2-test, P¼0.00024).
Moreover, on comparing GBMs and non-GBMs, we found that the
expression of hTERT was highly associated with GBMs (w
2-test,
P¼0.00003). Among non-GBMs, the expression of hTERT was
detected mainly in anaplastic oligodendrogliomas.
In hTERT-positive glioma samples, the number of hTERT
transcripts was assessed and normalised to the expression of a
housekeeping gene, ABL. Among glioma patients with detectable
hTERT mRNA, the hTERT/ABL ratio ranged between 2.6 and
180.1% (Figure 2). The hTERT/ABL ratio was significantly different
Table 1 Detection of hTERT mRNA in gliomas of varying type and
malignancy grade
hTERT mRNA
Type of glioma
WHO
grade
Number
of cases Positive Negative
Low-grade gliomas 14 1 (7.1%) 13 (92.9%)
Pilocytic astrocytoma I 3 0 3
Diffuse astrocytoma II 2 0 2
Oligoastrocytoma II 3 0 3
Oligodendroglioma II 6 1 5
Anaplastic gliomas 13 4 (30.8%) 9 (69.2%)
Anaplastic astrocytoma III 2 0 2
Anaplastic oligoastrocytoma III 3 0 3
Anaplastic oligodendroglioma III 8 4 4
Glioblastoma multiforme IV 43 30 (69.8%) 13 (30.2%)
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(Kruskal–Wallis test, P¼0.00013). Among patients with detect-
able levels of hTERT mRNA, the amount of hTERT transcripts
was significantly higher among the GBM patients (54.2%,
mean) than in non-GBMs (10.2%, mean) (Mann–Whitney U-test,
P¼0.012). Overall, the level of hTERT expression was neither
age- (Spearman rank test, NS) nor gender-related (Kruskal–Wallis
test, NS).
Prognostic significance of hTERT expression in GBMs
In the GBM group, we tested for a possible relation between the
relative level of hTERT expression and patient survival. The cases
with gross total tumour excision (n¼5), where no residual
contrast enhancement was detected on early postoperative
computed tomography scans, were excluded from analysis, as
complete resection of the lesion could influence favourably the
survival in GBMs (Scott et al, 1999). Among the 36 patients with
subtotal resection of their lesion, 25 had hTERT positive tumours.
In the hTERT-positive patient group, we determined, using an
ROC analysis, a cut-off level of hTERT transcripts of 23.7% that
best segregated patients into poor- and good-prognosis subgroups
(as described in the Statistical Analysis). We found that the
patients with high (425%) hTERT mRNA levels had significantly
shorter survival vs the patients with low (p25%) levels (log-rank
test, P¼0.0082, Figure 3). The 11 patients with non-detectable
hTERT mRNA had survival equivalent to that of high hTERT
expressors (log-rank test, P¼0.91, NS). The survival of these
patients was also significantly worse than that of patients with low
hTERT levels (log-rank test, P¼0.0064).
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Figure 1 Example of real-time PCR quantification of hTERT in tumour samples. Amplification profiles obtained on the LightCycler are presented for hTERT
(upper graph) and ABL (lower graph) transcripts. Linear regressions of standard dilution series, indicating accuracy of the analysis, are shown on the upper left
part of each graph. Calculation of the number of hTERT and ABL transcripts was done by using these standard curves. One of the standards was included in
each PCR run (amplification profiles shown as solid lines, 10
5 molecules). For each sample, the number of hTERT transcripts was divided by the number of
ABL transcripts in order to standardise the level of hTERT mRNA. The obtained ratios expressed as percentage are shown.
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In this study, we measured the hTERT mRNA level in tumour
specimens from a cohort of 70 patients with gliomas using a
recently introduced real-time quantitative PCR technique. We
found a progressive increase in the hTERT detection rate with
increasing grade of glioma malignancy: 7% for low-grade gliomas,
31% for anaplastic gliomas and 70% for GBMs. These data are in
agreement with the detection rates of telomerase activity reported
for these tumour types (Hiraga et al, 1998; Le et al, 1998; Harada
et al, 2000; Sugita et al, 2000). The association of hTERT
expression with GBMs was highly specific when comparing GBMs
to non-GBMs. This observation is in line with the recent
demonstration of a similar association at the level of hTERT-
protein overexpression (Chakravarti et al, 2001). Among
non-GBMs, hTERT mRNA was detectable in anaplastic oligoden-
drogliomas, consistent with a previous report (Langford et al,
1995). Among patients with detectable levels of hTERT mRNA, the
amount of hTERT transcripts was significantly higher among the
GBM patients. Taken together, these findings suggest that the level
of hTERT mRNA may be used as an indicator of enhanced glioma
malignancy. The hTERT analysis may complement histology and
help to refine tumour grading and classification.
Current system of pathological grading for human gliomas is
often nonprognostic: some tumours responding well to treatment
may be histologically indistinguishable from nonresponding ones.
Previous studies have suggested that telomerase activity in gliomas
may have utility in tumour prognosis, as the presence of such
activity has been correlated with a poor prognosis for low-grade
and anaplastic tumours (Nakatani et al, 1997; Hiraga et al, 1998;
Huang et al, 1999). However, studies have failed to identify any
significant relation between the level of telomerase activity and
patient survival in GBMs (Nakatani et al, 1997; Hiraga et al, 1998;
Kleinschmidt-Demasters et al, 2000). In the present study, we
found that among hTERT-positive GBM patients, the overall
survival was significantly worse in the patients with high levels of
hTERT mRNA. This finding is compatible with the result regarding
hTERT-protein overexpression in GBMs, which showed that high
levels of the protein correlated with reduced patient survival
(Chakravarti et al, 2001). Importantly, the patients without
detectable hTERT mRNA had a short survival equivalent to that
of high hTERT expressors. In contrast, the patients with low levels
of hTERT had prolonged survival. Thus, the level of hTERT mRNA
may predict decreased or increased survival in GBMs.
The level of hTERT mRNA estimated with real-time RT–PCR
procedure is the average amount of transcripts in a whole tumour
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Figure 2 Individual hTERT/ABL ratios (%) determined in glioma samples
according to the investigated tumour types. The mean values are shown as
horizontal bars for each group: low-grade tumours (0.2%), anaplastic
gliomas (3.7%), GBMs (37.8%).
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Figure 3 Survival of GBM patients in relation to hTERT status in their tumours. Patients, whose tumours expressed hTERT at low levels, survived
significantly longer (19 months, median) than those patients who showed high hTERT levels in their tumours (8 months, median) or than hTERT-negative
patients (8 months, median) did. Note the very similar survival period for high hTERT expressors and hTERT-negative patients.
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present in the tumour tissue. Studies of hTERT-protein distribu-
tion using immunohistochemistry in cultured cells and tissue
sections have shown that hTERT expression was detected in almost
all neoplastic cells in cancer tissues with high telomerase activity,
whereas cancers with low telomerase activity had fewer hTERT-
positive cancer cells (Hiyama et al, 2001). The burden of hTERT-
positive cells probably reflects the degree of expansion of
clonogenic tumour cell population, which has a great selective
advantage and proliferation capacity provided by telomerase
activity. It is possible that the level of expansion correlates with
the size of clonogenic cell fraction. Thus, low hTERT expressors
might survive longer than high hTERT expressors since they are
likely to have fewer neoplastic stem cells at the time of diagnosis,
and cytotoxic treatments are in this case more efficient. Never-
theless, testing this hypothesis requires further studies of hTERT-
positive gliomas combining the evaluation of hTERT-protein
expression at the individual cell level and clonogenic assays.
Equally poor prognosis found for GBM patients in the groups
with high hTERT expression and without hTERT expression points
to the fact that aggressive growth of some GBMs may occur in the
absence of telomerase. Telomerase-negative GBMs might achieve
immortalisation by an alternative mechanism of telomere length
stabilisation. Evidence in support of this hypothesis has been
reported in a study of telomere length in gliomas (Morii et al,
1997). Compared with telomerase-positive gliomas, telomerase-
negative gliomas were found to have very long and heterogeneous
telomeres, characteristics seen in tumour cells that have acquired
an alternative mechanism for lengthening their telomeres. The
nature of this mechanism named alternative lengthening of
telomeres (ALT) and described in several tumour types is currently
unclear, but may involve nonreciprocal recombination between
telomeres (Bryan et al, 1997). Given the poor prognosis in hTERT-
negative patients, it seems important to investigate the possible
role of the ALT mechanism in malignant progression of GBMs.
In conclusion, hTERT mRNA expression may be used as a
molecular marker of glioma malignancy that may be particularly
helpful in diagnosing GBMs as a complement to existing
approaches. In addition, the level of hTERT transcripts appears
to predict in GBMs decreased or increased survival. In the
development and future application of anti-telomerase treatments
of malignant gliomas (Komata et al, 2002), hTERT analysis of any
given tumour will be essential.
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